BioMarin details Alesta deal charges, confirms no change to prior 2026 guidance basis

BioMarin Pharmaceutical Inc. disclosed in an 8-K dated October 6, 2026 the expected financial impact of its acquisition of Alesta Therapeutics B.V., a Dutch private company, which was completed on August 31, 2026¹.

The company said its GAAP and non-GAAP financial results for the third quarter of 2026 are expected to include pre-tax charges of approximately $283 million of acquired in-process research and development (IPR&D) expense¹. BioMarin said the IPR&D charge and ongoing operating expenses represent an unfavorable impact of approximately $1.50 to both GAAP Diluted EPS and Non-GAAP Diluted EPS for the third quarter of 2026¹.

Because the timing and size of such deals are hard to predict, BioMarin said it does not forecast acquired IPR&D charges because the occurrence, magnitude, and timing of these transactions are inherently uncertain, and its full-year 2026 guidance previously announced on August 6, 2026, did not reflect the acquisition of Alesta¹.

For the full year, BioMarin said the Alesta deal is expected to produce total pre-tax charges of approximately $320 million for the full year 2026, consisting of the acquired IPR&D charges mentioned above and ongoing operating expenses, including transaction and transition costs¹. The company said these charges represent an unfavorable impact of approximately $1.55 to both GAAP Diluted EPS and Non-GAAP Diluted EPS for the full year 2026¹, and that it expects to provide updated full-year 2026 guidance in connection with its third quarter 2026 financial results¹.

BioMarin cautioned that results for the quarter ended September 30, 2026 have not been finalized and are subject to its financial statement closing procedures, and there can be no assurance that actual results will not differ from the preliminary estimates described¹.